Clinical trials: PD-L1 Positive
Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging
Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy
The goal of this observational study is to explore the application of temporal diffusion spectroscopy MRI in head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy
- Trial name
- NCT05964595
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC